Modernaの空売り状況は、投資家がModernaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Moderna (NASDAQ:MRNA) 株価情報, 空売り情報

MODERNA INC

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Large Cap

News

Movers

APTV

BGNE

BIRK

MRNA

POOL

先週の株価下落率上位10社に名を連ねたのは以下の銘柄だ。投資家はこれらの銘柄を保有しているだろうか？

米製薬大手モデルナ　米国市場を牽引

Moderna Inc

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) shares dipped 15.38% after UBS downgraded the stock from Buy to Neutral and <a href="https://www.benzinga.com/quote/beke/analyst-ratings" target="_blank" rel="noreferrer noopener">announced a price forecast of $24.5</a>.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) stock fell 9.76%. The stock briefly surged after Google announced an expanded partnership with Reddit, aiming to integrate Reddit content more <a href="https://www.benzinga.com//node/44369039" target="_blank" rel="noreferrer noopener">effectively across Google's products</a>.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock dived 8.75% after reporting topline results from two Phase 3 clinical trials of Povorcitinib in <a href="https://www.benzinga.com//node/44356786" target="_blank" rel="noreferrer noopener">patients with Hidradenitis Suppurativa</a>. William Blair and Guggenheim downgraded the stock, and Truist Securities cut its <a href="https://www.benzinga.com/quote/incy/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $74 to $72</a>.</li>
<li>James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) shares decreased 8.39%.</li>
<li>XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares dipped 8.13% after the company reported a <a href="https://www.benzinga.com//node/44373548" target="_blank" rel="noreferrer noopener">fourth-quarter adjusted EPS miss</a>.</li>
<li>Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) shares decreased 7.63% after the company issued first-quarter adjusted<a href="https://www.benzinga.com//node/44426184" target="_blank" rel="noreferrer noopener"> EPS guidance below estimates</a>.</li>
<li>Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) stock fell 7.22%. The company said it is entering into a strategic partnership with Shield AI to deliver AI-powered autonomous solutions <a href="https://www.benzinga.com//node/44378015" target="_blank" rel="noreferrer noopener">for the U.S. government</a>.</li>
<li>Telus Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) shares decreased 7.07%.</li>
<li>Futu Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) stock declined 7.01%, probably after the People's Bank of China kept the one-year loan prime rate at 3.1% and the five-year rate at 3.6%. Policymakers are navigating how to support economic growth while stabilizing the yuan amid rising trade tensions.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares lost 6.02% last week after Rosenblatt cut its <a href="https://www.benzinga.com/quote/MU/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from</a> $250 to $200. The company reported <a href="https://www.benzinga.com//node/44425486" target="_blank" rel="noreferrer noopener">Q2 financial results</a>.</li>
</ol>
Image by Robert Way via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44450329/robinhood-roku-and-shopify-are-among-top-10-large-cap-gainers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?</a></li>
</ul>

Equities

BEKE

FUTU

INCY

RDDT

XPEV

XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

JP Morgan analyst Jessica Fye maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Underweight and lowers the price target from $40 to $33.

Price Target

Analyst Ratings

JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $33

Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 10 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $977,910, and 2 were calls, valued at $135,544.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $150.0 for Moderna over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Moderna stands at 3553.6, with a total volume reaching 24,794.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $25.0 to $150.0, throughout the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742493702_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.75</td>
<td>$8.45</td>
<td>$8.5</td>
<td>$30.00</td>
<td>$579.7K</td>
<td>3.1K</td>
<td align="right">687</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.9</td>
<td>$45.00</td>
<td>$108.3K</td>
<td>7.5K</td>
<td align="right">357</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.47</td>
<td>$2.46</td>
<td>$2.47</td>
<td>$25.00</td>
<td>$87.4K</td>
<td>6.1K</td>
<td align="right">454</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.4</td>
<td>$4.35</td>
<td>$4.4</td>
<td>$35.00</td>
<td>$82.7K</td>
<td>816</td>
<td align="right">216</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.4</td>
<td>$5.35</td>
<td>$5.35</td>
<td>$35.00</td>
<td>$60.4K</td>
<td>7.6K</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 2,111,612, with MRNA's price up by 0.24%, positioned at $33.4.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 42 days.</li>
</ul>
<h3>Expert Opinions on Moderna</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $59.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Moderna, targeting a price of $78. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $40.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Moderna's Options: A Look at What the Big Money is Thinking

10 analysts have shared their evaluations of Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $57.1, a high estimate of $99.00, and a low estimate of $34.00. Highlighting a 30.27% decrease, the current average has fallen from the previous average price target of $81.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1741874592_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Moderna by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$78.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$34.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$51.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$99.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$108.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Moderna's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Moderna analyst ratings.</a>
<h2>Unveiling the Story Behind Moderna</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Financial Milestones: Moderna's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Moderna faced challenges, resulting in a decline of approximately -66.01% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Moderna's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -117.15%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Moderna's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.81%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Moderna's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.48%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.07, Moderna adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Biotech

General

Moderna Exec Says Co Expects "Little Bit More Of A Business As Usual" In Terms Of Vaccine-Related Meetings As Confirmations For Key Healthcare Roles Take Place

Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 17 unusual trades.
Delving into the details, we found 47% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $295,190, and 11 were calls, valued at $528,166.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.5 to $140.0 for Moderna over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3103.07 with a total volume of 1,821.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $22.5 to $140.0 over the last 30 days.
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741630530_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$93.8</td>
<td>$93.35</td>
<td>$93.54</td>
<td>$130.00</td>
<td>$93.5K</td>
<td>12</td>
<td align="right">10</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.3</td>
<td>$6.05</td>
<td>$6.3</td>
<td>$40.00</td>
<td>$83.1K</td>
<td>2.1K</td>
<td align="right">154</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$9.0</td>
<td>$8.65</td>
<td>$9.0</td>
<td>$45.00</td>
<td>$81.9K</td>
<td>528</td>
<td align="right">91</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$9.35</td>
<td>$9.15</td>
<td>$9.35</td>
<td>$60.00</td>
<td>$73.8K</td>
<td>1.0K</td>
<td align="right">82</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$8.4</td>
<td>$8.0</td>
<td>$8.25</td>
<td>$45.00</td>
<td>$57.7K</td>
<td>2.9K</td>
<td align="right">128</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Moderna</h3>
<ul>
<li>Trading volume stands at 7,873,478, with MRNA's price up by 2.89%, positioned at $36.64.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 52 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $49.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Sector Perform with a new price target of $40. 
&#x2A; An analyst from B of A Securities has decided to maintain their Underperform rating on Moderna, which currently sits at a price target of $34. 
&#x2A; An analyst from Barclays has revised its rating downward to Equal-Weight, adjusting the price target to $45. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Moderna, which currently sits at a price target of $78. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding Moderna's Options Activity: What's the Big Picture?

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Okta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) shares jumped 24.26% after the company reported <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/03/44108947/okta-stock-is-surging-tuesday-heres-why" target="_blank" rel="noreferrer noopener">better-than-expected</a> Q4 financial results, and several analysts upgraded the <a href="https://www.benzinga.com/quote/BJ/analyst-ratings" target="_blank" rel="noreferrer noopener">stock and raised price forecast</a>.</li>
<li>Arcelor Mittal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>) stock escalated 19.50% amid strength in gold and silver.</li>
<li>ING Groep (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ING#NYSE">ING</a>) stock was up 16.98% after the company announced a €70 million share repurchase program.</li>
<li>POSCO HOLDINGS INC. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKX#NYSE">PKX</a>) shares escalated 15.55% amid overall market strength, fueled by reports that President Trump will delay auto tariffs.</li>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares upped 15.02% after CEO Stephane Bancel Disclosed a share purchase.</li>
<li>Elbit Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) stock rose 14.80%.</li>
<li>BJ&#8217;s Wholesale Club Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) stock gained 14.06% after the company reported better-than-expected <a href="https://www.benzinga.com//node/44165337" target="_blank" rel="noreferrer noopener">Q4 financial results</a>. Several analysts <a href="https://www.benzinga.com/quote/BJ/analyst-ratings" target="_blank" rel="noreferrer noopener">raised their price forecast</a> on the stock.</li>
<li>Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) stock grew 12.64%.</li>
<li>Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) shares jumped 12.61%, probably after China reportedly set a 2025 GDP growth target of around 5% and unlocked stimulus measures.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares rose 12.43% as Bitcoin (CRYPTO: <a href="https://www.benzinga.com/quote/btc/usd" target="_blank" rel="noreferrer noopener">BTC</a>) <a href="https://www.benzinga.com//node/44138476" target="_blank" rel="noreferrer noopener">moved closer to the $90,000 mark</a>.</li>
</ol>
Image via Shutterstock

Trading Ideas

ESLT

MSTR

OKTA

TCOM

Okta, Moderna and MicroStrategy Are Among Top 10 Large-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?

<ul>
<li>CDC study follows measles outbreak amid declining vaccination rates</li>
<li>Kennedy's mixed messages on vaccines raise concerns</li>
<li>Autism rise attributed to broader screening, not vaccines</li>
</ul>
March 7 - The U.S. Centers for Disease Control and Prevention is planning a large study into potential connections between vaccines and autism, two sources familiar with the matter told Reuters, despite extensive scientific research that has disproven or failed to find evidence of such links.
It is unclear whether U.S. Health Secretary Robert F. Kennedy Jr, who has long promoted <a href="reuters://REALTIME/verb=NewsStory/ric=nL2N3PH1HA">anti-vaccine views</a>, is involved in the planned CDC study or how it would be carried out. The CDC and the Department of Health and Human Services were not immediately available for comment.
The CDC's move comes amid one of the largest <a href="reuters://REALTIME/verb=NewsStory/ric=nL3N3PN1WV">measles outbreaks</a> the U.S. has seen in the past decade, with more than 150 cases and two deaths in Texas and New Mexico. The outbreak has been fueled by declining vaccination rates in parts of the United States where parents have been falsely persuaded that such shots do more harm than good.
Kennedy, whose role includes authority over the CDC, has long sowed doubt over the safety of the combined vaccine for measles, mumps and rubella (MMR). In a cabinet meeting last week, Kennedy initially downplayed news that a school-aged child had died of measles in Texas, the first such death in a decade, calling such outbreaks ordinary and failing to mention the role of vaccination to prevent measles.
Over the weekend, Kennedy published an opinion piece on Fox News that promoted the role of vaccination, but also told parents vaccination was a personal choice and urged them to consult with their physician.
Kennedy did not immediately respond to a request for comment.
Autism diagnoses in the United States have increased significantly since 2000, intensifying public concern.
Many researchers attribute the <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3NJ17A">rise in diagnoses</a> to more widespread screening and the inclusion of a broader range of behaviors to describe the condition. But some public figures have popularized the idea that vaccines are to blame, an idea stemming from a since-debunked study from British researcher Andrew Wakefield in the late 1990s that connected a rise in autism diagnoses with widespread use of the MMR shot.
The causes of autism are unclear. No rigorous studies have found links between autism and vaccines or medications, or their components such as thimerosal or formaldehyde.
There is widespread speculation among scientists that its neurological characteristics may develop in utero, when the fetal brain is being wired. Studies have linked autism to maternal factors in pregnancy, and some research suggests a link to birth complications and timing.
President Donald Trump, in an address to Congress this week, cited the rise in autism among children. "So, we're going to find out what it is, and there's nobody better than Bobby and all of the people that are working with you," Trump said, referring to Kennedy.
Kennedy's anti-vaccine views have drawn concern among some Republicans. During Kennedy's confirmation hearing Senator Bill Cassidy, a Louisiana Republican and physician, suggested that the nominee disavow any links between vaccines and autism.
Kennedy denied that he was anti-vaccine, but did not acknowledge that such a link had been debunked.
This week Cassidy questioned Trump's nominee to lead the National Institutes of Health, Dr. Jay Bhattacharya, over his stance on investigating a potential link between autism and childhood vaccinations.
"I don't generally believe there is a link, based on my reading of the literature," Bhattacharya said. "But we do have a sharp rise in autism rates, and I don't think any scientist really knows the cause of it. I would support a broad scientific agenda based on data to get an answer to that."

BNTX

'U.S. CDC Plans Large Study Into Potential Connections Between Vaccines And Autism, Sources Say' - Reuters News

Legal

Global

German Court Rules In Favor Of Moderna In Patent Lawsuit Against BioNTech And Pfizer; German Court Rules Pfizer, BioNTech Violated Moderna's Covid-19 Vaccine Patents

WIIM

Moderna shares are trading higher after CEO Stephane Bancel Disclosed a share purchase.

MRNA: 10% &#x7C; <a href="https://www.benzinga.com//node/44127329">Moderna shares are trading higher after Stephane Bancel Disclosed a share purchase.</a>
&nbsp;
OPFI: 13% &#x7C; <a href="https://www.benzinga.com//node/44137968">OppFi shares are trading higher after the company reported better-than-expected Q4 financial results and issued strong guidance.</a>
&nbsp;
AVAV: -20% &#x7C; <a href="https://www.benzinga.com//node/44126436">AeroVironment shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY25 guidance below estimates.</a>

AVAV

OPFI

Market-Moving News for March 5th

Moderna shares are trading higher after Stephane Bancel Disclosed a share purchase.

Insider Trades

Moderna CEO Stephane Bancel Discloses Open Market Purchase Of 160,314 Shares At Avg. Price $31.22

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 26 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 53%, bearish.
Out of all of the special options we uncovered, 15 are puts, for a total amount of $2,799,688, and 11 are calls, for a total amount of $618,935.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $80.0 for Moderna over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Moderna's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $25.0 to $80.0 in the last 30 days. 
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741119339_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$6.35</td>
<td>$6.2</td>
<td>$6.21</td>
<td>$30.00</td>
<td>$931.5K</td>
<td>8.4K</td>
<td>1.5K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.35</td>
<td>$13.3</td>
<td>$13.3</td>
<td>$40.00</td>
<td>$931.0K</td>
<td>9.4K</td>
<td>700</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$14.75</td>
<td>$13.45</td>
<td>$14.75</td>
<td>$40.00</td>
<td>$187.3K</td>
<td>511</td>
<td>128</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$7.25</td>
<td>$7.1</td>
<td>$7.18</td>
<td>$30.00</td>
<td>$143.9K</td>
<td>13.3K</td>
<td>237</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$6.8</td>
<td>$6.75</td>
<td>$6.8</td>
<td>$25.00</td>
<td>$142.1K</td>
<td>2.0K</td>
<td>209</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Moderna</h3>
<ul>
<li>With a trading volume of 5,515,339, the price of MRNA is down by -1.55%, reaching $29.8.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 58 days from now.</li>
</ul>
<h3>What The Experts Say On Moderna</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $49.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for Moderna, targeting a price of $34. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Moderna, targeting a price of $78. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Sector Perform with a new price target of $40. 
&#x2A; An analyst from Barclays has revised its rating downward to Equal-Weight, adjusting the price target to $45. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Moderna Unusual Options Activity

ABUS

ROIV

Roviant Sciences Subsidiary, Genevant Sciences, And Arbutus Biopharma File Five International Patent Infringement Enforcement Actions Against Moderna

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 35% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $1,135,204 and 7, calls, for a total amount of $483,749.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $60.0 for Moderna over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Moderna stands at 3878.9, with a total volume reaching 3,512.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $30.0 to $60.0, throughout the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740768380_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$6.2</td>
<td>$6.0</td>
<td>$6.15</td>
<td>$30.00</td>
<td>$615.0K</td>
<td>1.9K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.05</td>
<td>$6.95</td>
<td>$7.05</td>
<td>$30.00</td>
<td>$282.0K</td>
<td>13.7K</td>
<td>408</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.75</td>
<td>$2.53</td>
<td>$2.74</td>
<td>$40.00</td>
<td>$134.1K</td>
<td>4.0K</td>
<td>569</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.4</td>
<td>$3.25</td>
<td>$3.4</td>
<td>$45.00</td>
<td>$98.9K</td>
<td>6.6K</td>
<td>7</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.45</td>
<td>$5.35</td>
<td>$5.35</td>
<td>$35.00</td>
<td>$96.2K</td>
<td>7.4K</td>
<td>543</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Current Position of Moderna</h3>
<ul>
<li>Currently trading with a volume of 4,492,595, the MRNA's price is down by -2.28%, now at $30.38. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>Expert Opinions on Moderna</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $49.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Moderna, which currently sits at a price target of $78. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Moderna with a target price of $34. 
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $40. 
&#x2A; Reflecting concerns, an analyst from Barclays lowers its rating to Equal-Weight with a new price target of $45.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$42.00</td>
<td>$33.4K</td>
<td>6.5K</td>
<td>5.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$27.00</td>
<td>$47.3K</td>
<td>322</td>
<td>2.3K</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$65.00</td>
<td>$28.0K</td>
<td>11.9K</td>
<td>672</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$87.00</td>
<td>$30.2K</td>
<td>6</td>
<td>500</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$43.00</td>
<td>$41.2K</td>
<td>5.7K</td>
<td>81</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$56.9K</td>
<td>1.9K</td>
<td>80</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$915.00</td>
<td>$32.2K</td>
<td>177</td>
<td>66</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$30.00</td>
<td>$34.0K</td>
<td>6.0K</td>
<td>50</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$520.00</td>
<td>$58.0K</td>
<td>962</td>
<td>40</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$310.00</td>
<td>$53.0K</td>
<td>38</td>
<td>19</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option trade that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $42.00 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $334.0 per contract. There were 6534 open contracts at this strike prior to today, and today 5139 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bearish sentiment. It expires in 29 day(s) on March 28, 2025. Parties traded 720 contract(s) at a $27.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $47.3K, with a price of $65.0 per contract. There were 322 open contracts at this strike prior to today, and today 2378 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option sweep that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $65.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 11949 open contracts at this strike prior to today, and today 672 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a put option trade that happens to be bearish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 144 contract(s) at a $87.00 strike. The total cost received by the writing party (or parties) was $30.2K, with a price of $210.0 per contract. There were 6 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a call option trade that happens to be bullish, expiring in 323 day(s) on January 16, 2026. This event was a transfer of 25 contract(s) at a $43.00 strike. The total cost received by the writing party (or parties) was $41.2K, with a price of $1650.0 per contract. There were 5751 open contracts at this strike prior to today, and today 81 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 323 day(s) on January 16, 2026. Parties traded 67 contract(s) at a $230.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $56.9K, with a price of $850.0 per contract. There were 1944 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with neutral sentiment. It expires in 8 day(s) on March 7, 2025. Parties traded 15 contract(s) at a $915.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $2150.0 per contract. There were 177 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
• Regarding BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we observe a call option trade with bullish sentiment. It expires in 78 day(s) on May 16, 2025. Parties traded 50 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $680.0 per contract. There were 6077 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bearish sentiment. It expires in 113 day(s) on June 20, 2025. Parties traded 10 contract(s) at a $520.00 strike. The total cost received by the writing party (or parties) was $58.0K, with a price of $5800.0 per contract. There were 962 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 204 day(s) on September 19, 2025. This event was a transfer of 19 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $53.0K, with a price of $2790.0 per contract. There were 38 open contracts at this strike prior to today, and today 19 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

BBIO

DXCM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

SWTX

10 Health Care Stocks Whale Activity In Today's Session

Moderna shares are trading lower following reports suggesting officials in the Trump administration are reconsidering $590 million in funding for the company's bird flu vaccine.

The Donald Trump administration is contemplating the withdrawal of a $590 million contract previously granted to&nbsp;Moderna Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) by the Biden administration. This contract was intended for the production of a bird flu vaccine.
What Happened: The U.S. health officials are currently scrutinizing Moderna&#8217;s avian flu vaccine contract as part of a broader review of government expenditure on messenger RNA-based vaccines, <a href="https://www.benzinga.com/news/25/02/43913228/trump-team-weighs-pulling-funding-for-moderna-bird-flu-vaccine">Bloomberg</a> reported. The contract, awarded during the final days of the Biden administration, shot up Moderna&#8217;s stock within two days of the announcement on January 17.
A spokesperson from Robert F. Kennedy Jr.-led Department of Health and Human Services (HHS) communicated that the review was necessitated by &#8220;four years of the Biden administration's failed oversight.&#8221; The spokesperson acknowledged the criticality of readiness for the pandemic but also underscored the need for careful examination of vaccine production contracts.
Moderna, having successfully completed an initial trial of the bird flu vaccine last year,&nbsp;was preparing for a&nbsp;large-scale final-stage trial. However, the absence of funding might impede the trial&#8217;s progress. The company has been grappling with the need to identify new revenue streams as the sales of its COVID-19 vaccine decline and it maintains significant investments in its pipeline.
The contract was hastily approved amid apprehensions that the Trump administration might be less inclined to finance vaccine manufacturers. Moderna has also been involved in a patent dispute with the National Institutes of Health regarding its vaccine.
SEE ALSO: <a href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs">Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs</a>
Why It Matters: The reconsideration of funding comes at a time when the Trump administration has <a href="https://www.benzinga.com/markets/25/02/43998434/trump-team-commits-1-billion-to-combat-bird-flu-lower-egg-prices-hopefully-by-summer-says-usda">committed $1 billion </a>to fight bird flu and bring down the rising egg prices. Notably, the commitment also includes an allocation of $100 million for vaccine research, though the poultry industry is divided on its implications. 
This development also coincides with a phase when influential personalities like <a href="https://www.benzinga.com/personal-finance/25/02/43913228/bill-gates-says-next-pandemic-can-emerge-anywhere-and-the-world-isnt-prepared-we-cant-afford-to-get-caught-flat-footed-again">Bill Gates</a> have warned about the potential for new pandemics and the world&#8217;s lack of preparedness. Gates has emphasized that we cannot afford to be caught off guard again, particularly after the devastating impact of COVID-19.
Kennedy, known for his vaccine skepticism and conspiracy theories, has extended his influence globally, undermining health initiatives like vaccination and AIDS prevention, The New York Times <a href="https://www.nytimes.com/2024/11/30/world/africa/rfk-jr-kennedy-international-work-public-health-policies.html" target="_blank" rel="noreferrer noopener">reports</a>. Through his nonprofit, Children&#8217;s Health Defense, Kennedy has <a href="https://www.benzinga.com/markets/equities/24/11/42254495/trumps-hhs-pick-rfk-jr-has-a-long-history-of-challenging-global-health-policies" target="_blank" rel="noreferrer noopener">disrupted public health efforts</a> in countries like Uganda and South Africa. He has also questioned the World Health Organization and its programs for fueling global health conspiracies.
Moderna stock has plunged over 65% during the last 12 months as per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
READ MORE: <a href="https://www.benzinga.com/25/02/43998608/tesla-continuing-to-upgrade-its-headquarters-in-texas-says-exec">Elon Musk&#8217;s Tesla Upgrades Giga Texas: Driverless Cars, Cybercab Preparations, GPU Training Cluster And More</a>

Trump's Officials To Re-Consider Moderna's $590 Million Bird Flu Vaccine Funding: RFK Jr-Led HHS Slams 'Biden Administration's Failed Oversight'

Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 63% bullish and 27%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $416,465, and 6 are calls, for a total amount of $243,109.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $180.0 for Moderna over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 2801.22 with a total volume of 3,398.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $25.0 to $180.0 over the last 30 days.
<h3>Moderna 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740600074_0_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$3.15</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$25.00</td>
<td>$210.0K</td>
<td>3.1K</td>
<td align="right">700</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$32.45</td>
<td>$32.2</td>
<td>$32.2</td>
<td>$65.00</td>
<td>$74.0K</td>
<td>106</td>
<td align="right">27</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.37</td>
<td>$2.19</td>
<td>$2.19</td>
<td>$60.00</td>
<td>$60.4K</td>
<td>1.3K</td>
<td align="right">277</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$32.45</td>
<td>$32.2</td>
<td>$32.2</td>
<td>$65.00</td>
<td>$57.9K</td>
<td>106</td>
<td align="right">45</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$0.6</td>
<td>$0.4</td>
<td>$0.55</td>
<td>$130.00</td>
<td>$49.4K</td>
<td>879</td>
<td align="right">900</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Currently trading with a volume of 4,514,474, the MRNA's price is up by 0.12%, now at $33.32. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 64 days.</li>
</ul>
<h3>What Analysts Are Saying About Moderna</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $49.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays has revised its rating downward to Equal-Weight, adjusting the price target to $45. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Moderna with a target price of $78. 
&#x2A; In a cautious move, an analyst from Goldman Sachs downgraded its rating to Neutral, setting a price target of $51. 
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $40. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for Moderna, targeting a price of $34. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of Moderna's Latest Options Trends

Earnings

Press Releases

Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025

Small Cap

Opinion

Potential Revolution in Healthcare Brewing, Powered by AI Innovation

Bird Flu Leads To Egg Shortages And Price Rise In America

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health

Penny Stocks

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

Events

Moderna to Present at Upcoming Conferences in March 2025

Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

Commodities

Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

AVAI

AVTE

CTRX

DVAX

FHTX

GEHC

HPTX

HZNP

SANA

TARS

TDOC

ZNTL

ZSPH

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

JP Morgan

Citigroup

RBC Capital

Barclays

Screenshot 2024-04-30 at 5.36.02 PM

Health Care

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Comments

Moderna

空売り

Moderna (NASDAQ:MRNA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル